However, the patients included in this study did not have a formal diagnosis of NAFLD, and basal GGT levels were significantly higher in the lower percentile of SAT and VAT ZAG gene expression levels, which could have led to greater benefits after BS in this population due to altered baseline characteristics. The gene discussed is AZGP1; the disease is metabolic dysfunction-associated steatotic liver disease.